Clinical Trials
32 trialsNCT03093116 2026-05-27
TRIDENT-1
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03504397 2026-05-04
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT02576431 2026-04-28
NAVIGATE
Bayer
Phase 2 Completed
NCT01682083 2026-04-21
COMBI-AD
Novartis
Phase 3 Completed
NCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT03157128 2026-04-16
LIBRETTO-001
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT02864992 2026-04-13
VISION
EMD Serono
Phase 2 Active not recruiting
NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT01909453 2026-02-27
COLUMBUS
Pfizer
Phase 3 Completed
NCT02715284 2026-01-13
GARNET
Tesaro, Inc.
Phase 1 Active not recruiting
NCT03899792 2026-01-06
LIBRETTO-121
Eli Lilly and Company
Phase 1/2 Active not recruiting
NCT01743131 2025-12-11
Abatacept as GVHD Prophylaxis Phase 2
Boston Children's Hospital
Phase 2 Completed
NCT03539536 2025-11-05
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
AbbVie
Phase 2 Active not recruiting
NCT03785249 2025-09-30
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Mirati Therapeutics Inc.
Phase 1/2 Active not recruiting
NCT03470922 2025-09-09
RELATIVITY-047
Bristol-Myers Squibb
Phase 2/3 Active not recruiting
NCT03981796 2025-09-03
RUBY
Tesaro, Inc.
Phase 3 Active not recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT05409066 2025-07-28
EPCORE FL-1
Genmab
Phase 3 Active not recruiting
NCT02637687 2025-06-22
SCOUT
Bayer
Phase 1/2 Active not recruiting
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT02437318 2025-02-13
SOLAR-1
Novartis
Phase 3 Completed
NCT03212404 2025-02-03
Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers
Checkpoint Therapeutics, Inc.
Phase 1 Active not recruiting
NCT01121588 2025-01-23
Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)
Pfizer
Phase 1 Terminated
NCT02393859 2024-05-29
Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)
Amgen
Phase 3 Completed
NCT02564900 2024-01-22
Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors
Daiichi Sankyo
Phase 1 Completed
NCT02422615 2023-11-30
MONALEESA-3
Novartis
Phase 3 Completed
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT02501096 2023-07-20
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
Eisai Inc.
Phase 1/2 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT01336634 2022-04-04
Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.
Novartis
Phase 2 Completed
NCT02124772 2021-07-14
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
Phase 1/2 Completed